Hansa Biopharma — Juni 2024
-
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.
Yahoo Finance (finance.yahoo.com)
Sarepta stock jumped Thursday after Pfizer's (PFE) rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.
-
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
The failure of another trial adds to uncertainty around the benefits of the gene-based treatments, though industry analysts still expect Sarepta’s Elevidys’ to be unaffected.
BioPharma Dive (www.biopharmadive.com)
-
High-level data fra forsøget forventes i 2024.
-
FDA undersøger pt. mulig udvidelse af Elevidys-brug - der stilles flere gode spørgsmål i artiklen.
FDA-afgørelse forventes nu på fredag d. 21. juni.
Denne FDA-afgørelse er af stor betydning for Hansa Biopharma, da de forventer at markedsføre deres imlifidase-produkt som en forbehandling til Elevidys.
-
"Besides the $10m upfront Hansa has already received, it is eligible to receive up to $397.5 million in milestone payments and up to mid-teens in royalty revenues on SRP-9001 for DMD and Limb girdle muscular dystrophies (LGMD), in additional to all imlifidase sales."
(Kilde: Intron Health 06/03/2023)
-
-
D.d. EI: "Dansk biotekselskab buldrer videre op" er da fx en pæn hypet overskrift.
"setback brings questions for Duchenne gene therapy"-linket har jeg netop medtaget for at få flere nuancer/modspil med her i Hansa Biopharma-tråden .. men forstår bestemt din pointe
-
Nytt läkemedel inaktiverar antikroppar
"Upptäckten av en ny molekyl 2001 har 20 år senare lett fram till en behandling som kan hjälpa fler att transplanteras. Läkemedlet är nu tillgängligt för svenska patienter."
Nytt läkemedel inaktiverar antikroppar - Njurförbundet
Mer än var tionde njursjuk patient är ”högsensitiserad” vilket innebär att de har antikroppar som gör att transplantation hittills inte...
Njurförbundet (njurforbundet.se)
Publicerad 2021-09-16
Idefirix
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind